IL238554A0 - Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responses - Google Patents
Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responsesInfo
- Publication number
- IL238554A0 IL238554A0 IL238554A IL23855415A IL238554A0 IL 238554 A0 IL238554 A0 IL 238554A0 IL 238554 A IL238554 A IL 238554A IL 23855415 A IL23855415 A IL 23855415A IL 238554 A0 IL238554 A0 IL 238554A0
- Authority
- IL
- Israel
- Prior art keywords
- modulators
- amide
- alkyl
- compounds useful
- substituted pyridyl
- Prior art date
Links
- 125000004076 pyridyl group Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723854P | 2012-11-08 | 2012-11-08 | |
| PCT/US2013/068842 WO2014074660A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL238554A0 true IL238554A0 (en) | 2015-06-30 |
Family
ID=49667568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238554A IL238554A0 (en) | 2012-11-08 | 2015-04-30 | Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responses |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9315494B2 (enExample) |
| EP (1) | EP2922841B8 (enExample) |
| JP (1) | JP6259463B2 (enExample) |
| KR (1) | KR102233252B1 (enExample) |
| CN (1) | CN104781252B (enExample) |
| AR (1) | AR093403A1 (enExample) |
| AU (1) | AU2013341185B2 (enExample) |
| BR (1) | BR112015010244A8 (enExample) |
| CA (1) | CA2890929A1 (enExample) |
| EA (1) | EA028526B1 (enExample) |
| IL (1) | IL238554A0 (enExample) |
| MX (1) | MX2015005272A (enExample) |
| SG (1) | SG11201503396UA (enExample) |
| TW (1) | TWI620737B (enExample) |
| WO (1) | WO2014074660A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890935A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| AU2013341186B2 (en) | 2012-11-08 | 2017-03-30 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| AR098991A1 (es) | 2014-01-03 | 2016-06-22 | Bristol Myers Squibb Co | Compuestos de nicotinamida sustituida con heteroarilo |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| WO2016022626A1 (en) * | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP3313844B1 (en) | 2015-06-24 | 2020-08-26 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| CN109641906B (zh) | 2015-06-24 | 2021-10-01 | 百时美施贵宝公司 | 杂芳基取代的氨基吡啶化合物 |
| PT3757097T (pt) * | 2015-11-26 | 2022-06-20 | Novartis Ag | Derivados de diamino piridina |
| CN115448916B (zh) | 2016-10-14 | 2026-04-28 | 武田药品工业株式会社 | Tyk2抑制剂及其用途 |
| JP7082120B2 (ja) | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| KR102602558B1 (ko) * | 2016-12-13 | 2023-11-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서의 포스핀 옥시드 알킬 아미드 치환된 헤테로아릴 화합물 |
| TWI868528B (zh) | 2017-03-08 | 2025-01-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑之生產方法 |
| SG11201908947QA (en) * | 2017-03-30 | 2019-10-30 | Bristol Myers Squibb Co | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| RS62430B1 (sr) | 2017-05-11 | 2021-11-30 | Bristol Myers Squibb Co | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori |
| TWI776810B (zh) * | 2017-05-12 | 2022-09-11 | 瑞士商諾華公司 | 新穎二胺基吡啶衍生物 |
| WO2019023468A1 (en) | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| IL274816B2 (en) * | 2017-11-21 | 2023-12-01 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11685723B2 (en) | 2018-02-13 | 2023-06-27 | Rutgers, The State University Of New Jersey | Antibacterial agents: O-alkyl-deuterated pyronins |
| WO2019160875A1 (en) | 2018-02-13 | 2019-08-22 | Rutgers, The State University Of New Jersey | Antibacterial agents: soluble salts and aqueous formulations of pyronins |
| US11572337B2 (en) | 2018-03-06 | 2023-02-07 | Rutgers, The State University Of New Jersey | Antibacterial agents: arylalkylcarboxamido phloroglucinols |
| US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| EP3768667B1 (en) * | 2018-03-22 | 2023-04-12 | Bristol-Myers Squibb Company | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| CA3115088A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CA3118094A1 (en) * | 2018-10-30 | 2020-05-07 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| AU2020212001A1 (en) | 2019-01-23 | 2021-07-22 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| CN115448910B (zh) * | 2019-01-28 | 2024-04-19 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP3999512B1 (en) | 2019-07-18 | 2023-08-23 | Bristol-Myers Squibb Company | Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors |
| ES2961950T3 (es) | 2019-07-18 | 2024-03-14 | Bristol Myers Squibb Co | Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4 |
| JP7573596B2 (ja) | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| JP7682154B2 (ja) | 2019-08-06 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な二環ヘテロ環式化合物 |
| EP4013758B1 (en) | 2019-08-13 | 2025-12-24 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| PH12022550605A1 (en) | 2019-09-13 | 2023-09-25 | Nimbus Saturn Inc | Hpk1 antagonists and uses thereof |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| JP7682191B2 (ja) | 2020-02-03 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環ヘテロアリール化合物 |
| CN112203515B (zh) * | 2020-03-11 | 2022-08-02 | 西北农林科技大学 | N-苄基苯甲酰胺类化合物作为除草剂的用途 |
| US20230295119A1 (en) * | 2020-04-14 | 2023-09-21 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| US12479831B2 (en) | 2020-04-28 | 2025-11-25 | Bristol-Myers Squibb Company | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators |
| JP7537002B2 (ja) * | 2020-08-07 | 2024-08-20 | 南京薬石科技股▲フン▼有限公司 | Ｃｄｋ９阻害剤およびその使用 |
| CN114181257B (zh) * | 2020-09-14 | 2025-02-14 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物，包含其的药物组合物，其制备方法及其用途 |
| JP2023546996A (ja) | 2020-10-23 | 2023-11-08 | ニンバス クロソー， インコーポレイテッド | Ｃｔｐｓ１阻害剤およびその使用 |
| EP4263523A2 (en) * | 2020-12-16 | 2023-10-25 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2022147465A1 (en) | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| WO2022174253A1 (en) | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| JP2024507253A (ja) * | 2021-02-19 | 2024-02-16 | スドー バイオサイエンシーズ リミテッド | Ｔｙｋ２阻害剤およびその使用 |
| CA3207819A1 (en) * | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| CN117120440A (zh) * | 2021-02-19 | 2023-11-24 | 苏多生物科学有限公司 | Tyk2抑制剂及其用途 |
| CN117242072A (zh) * | 2021-02-19 | 2023-12-15 | 苏多生物科学有限公司 | Tyk2抑制剂及其用途 |
| JP2024508794A (ja) | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | Ｔｙｋ２阻害剤およびその使用 |
| CN117377669A (zh) * | 2021-02-19 | 2024-01-09 | 苏多生物科学有限公司 | Tyk2抑制剂及其用途 |
| US20240189309A1 (en) * | 2021-02-19 | 2024-06-13 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| CN117295737A (zh) | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| EP4319756A4 (en) | 2021-04-09 | 2025-02-26 | Nimbus Clio, Inc. | CBL-B MODULATORS AND USES THEREOF |
| IL308422A (en) * | 2021-05-14 | 2024-01-01 | Bristol Myers Squibb Co | substituted heterocyclic compounds |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| JP2025503448A (ja) * | 2021-12-16 | 2025-02-04 | リンク ファーマシューティカルズ シーオー．エルティーディー． | Ｔｙｋ２阻害剤および組成物ならびにその方法 |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| US20250270190A1 (en) * | 2022-04-19 | 2025-08-28 | Blueprint Medicines Corporation | Kit inhibitors |
| EP4532485A1 (en) * | 2022-05-27 | 2025-04-09 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| JP2025527250A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用 |
| JP2025527248A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用 |
| JP2025527247A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用 |
| WO2024249855A1 (en) * | 2023-06-02 | 2024-12-05 | Idrx, Inc. | Combination therapy comprising kit inhibitors for use in the treatment of cancer |
| AU2024344754A1 (en) | 2023-09-21 | 2026-04-02 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JPWO2010058846A1 (ja) * | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| EP2638018A1 (en) * | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
-
2013
- 2013-11-07 AR ARP130104094A patent/AR093403A1/es unknown
- 2013-11-07 MX MX2015005272A patent/MX2015005272A/es unknown
- 2013-11-07 KR KR1020157014693A patent/KR102233252B1/ko not_active Expired - Fee Related
- 2013-11-07 EP EP13795911.0A patent/EP2922841B8/en active Active
- 2013-11-07 US US14/441,193 patent/US9315494B2/en active Active
- 2013-11-07 WO PCT/US2013/068842 patent/WO2014074660A1/en not_active Ceased
- 2013-11-07 BR BR112015010244A patent/BR112015010244A8/pt not_active Application Discontinuation
- 2013-11-07 SG SG11201503396UA patent/SG11201503396UA/en unknown
- 2013-11-07 TW TW102140570A patent/TWI620737B/zh not_active IP Right Cessation
- 2013-11-07 EA EA201590913A patent/EA028526B1/ru not_active IP Right Cessation
- 2013-11-07 CA CA2890929A patent/CA2890929A1/en not_active Abandoned
- 2013-11-07 JP JP2015541882A patent/JP6259463B2/ja active Active
- 2013-11-07 AU AU2013341185A patent/AU2013341185B2/en not_active Ceased
- 2013-11-07 CN CN201380058022.7A patent/CN104781252B/zh active Active
-
2015
- 2015-04-30 IL IL238554A patent/IL238554A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6259463B2 (ja) | 2018-01-10 |
| BR112015010244A2 (pt) | 2017-07-11 |
| KR20150081338A (ko) | 2015-07-13 |
| US20150307483A1 (en) | 2015-10-29 |
| JP2016506368A (ja) | 2016-03-03 |
| EA201590913A1 (ru) | 2015-10-30 |
| US9315494B2 (en) | 2016-04-19 |
| SG11201503396UA (en) | 2015-05-28 |
| EP2922841A1 (en) | 2015-09-30 |
| EP2922841B8 (en) | 2017-08-02 |
| BR112015010244A8 (pt) | 2019-10-01 |
| AU2013341185A1 (en) | 2015-07-02 |
| KR102233252B1 (ko) | 2021-03-26 |
| CA2890929A1 (en) | 2014-05-15 |
| CN104781252A (zh) | 2015-07-15 |
| EA028526B1 (ru) | 2017-11-30 |
| AU2013341185B2 (en) | 2017-07-13 |
| EP2922841B1 (en) | 2017-06-07 |
| WO2014074660A1 (en) | 2014-05-15 |
| TW201422587A (zh) | 2014-06-16 |
| AR093403A1 (es) | 2015-06-03 |
| TWI620737B (zh) | 2018-04-11 |
| CN104781252B (zh) | 2017-11-17 |
| MX2015005272A (es) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201503396UA (en) | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES | |
| HUS2300025I1 (hu) | Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai | |
| IL245448B (en) | Alkyl-amide substituted pyridyl compounds useful as modulators of responses to il-12, il-23, and/or ifnalpha | |
| IL244081A0 (en) | Preparations and methods for modulating RNA | |
| IL237156B (en) | Microcapsule preparation and methods | |
| ZA201409071B (en) | Controlled environment and method | |
| IL238605A (en) | Converted pyrimidine compounds with alkylamide for use in modulation il-23, il-12, and / or ifnα | |
| PL2988756T5 (pl) | Formulacja środka kontrastowego i powiązany sposób jego wytwarzania | |
| EP3074039A4 (en) | Compositions and methods for modulating an immune response | |
| EP2854562A4 (en) | FOOD COMPOSITION AND METHOD | |
| GB201222820D0 (en) | Woolscouring method and composition | |
| SMT201900406T1 (it) | Composti piridilici alchil-ammide-sostitidti utili come modulatori delle risposte di il-12, il-23 e/o ifn-alfa | |
| ZA201500172B (en) | Plant-disease-control composition and plant-disease-control method | |
| GB201208476D0 (en) | Compositions and methods for modulating an immune response | |
| GB201222810D0 (en) | Woolscouring method and composition | |
| AU2013905090A0 (en) | Formulations and Method for Treating Diabetes | |
| GB201204512D0 (en) | Method and composition | |
| GB201218715D0 (en) | Novel method and products |